Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man.
Topical anti-inflammatory ('intracutaneous vasoconstriction') and systemic glucocorticoid potencies (depression of plasma cortisol) were compared in human volunteers after administration of the glucocorticoids budesonide, beclomethasone dipropionate (BDP) and prednisolone. After topical application budesonide was about twice as potent as BDP and more than 1 000 times more potent than prednisolone and hydrocortisone in inducing 'vasoconstriction'. After oral administration, on the other hand, budesonide was one half to one third as potent as BDP in depressing plasma cortisol. After inhalation budesonide was only half as potent as BDP. When inhaled budesonide was compared to oral prednisolone budesonide 1 600 micrograms and prednisolone 5 mg were shown to have the same effect on plasma cortisol. The improved ratio between the topical and the systemic glucocorticoid effect of budesonide, makes the drug a promising alternative for aerosol treatment in asthma.
D000328:Adult; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D019819:Budesonide; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use*
D011282:Pregnenediones; D019819:Budesonide; D011239:Prednisolone; D001507:Beclomethasone